Hormone Refractory Prostate Cancer Market Report 2026

The hormone refractory prostate cancer market size has grown rapidly in recent years. It will grow from $8.12 billion in 2025 to $8.95 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to rising incidence of advanced prostate cancer, widespread adoption of androgen deprivation therapy, increased availability of chemotherapy agents, growing use of psa-based disease monitoring, expansion of oncology care infrastructure.

The hormone refractory prostate cancer market size is expected to see strong growth in the next few years. It will grow to $13.09 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing development of targeted therapies, rising clinical trial activity in castration-resistant prostate cancer, growing demand for personalized oncology care, expansion of immuno-oncology pipelines, increasing healthcare expenditure on cancer treatments. Major trends in the forecast period include increasing adoption of precision oncology therapies, rising use of combination drug regimens, growing integration of biomarker-based treatment selection, expansion of immunotherapy applications in advanced prostate cancer, enhanced focus on personalized treatment pathways.

Increasing investment in cancer research is expected to drive the growth of the hormone-refractory prostate cancer market going forward. Cancer research investment refers to the allocation of funding and resources to support the development of innovative approaches for cancer detection, treatment, and prevention. The rise in cancer research investment is largely driven by the growing global cancer burden, which necessitates more effective and targeted therapeutic solutions. Investment in cancer research accelerates innovation in the treatment of hormone-refractory prostate cancer by supporting advanced therapies such as radioligand treatments and hormone inhibitors. It also finances clinical trials and biomarker studies to improve treatment precision and patient outcomes. For example, in August 2024, according to the Cancer Research Institute (CRI), a US-based nonprofit organization focused on advancing immunotherapy research, the institute invested approximately $22.8 million during the 2023-2024 fiscal year, funding 64 new research grants across 42 institutions in seven countries. Therefore, increasing investment in cancer research is fueling the growth of the hormone-refractory prostate cancer market.

Major companies operating in the hormone-refractory prostate cancer market are concentrating on the development of advanced therapies, such as intravenous radioligand therapy, to enhance survival outcomes for patients with treatment-resistant forms of the disease. Intravenous radioligand therapy is a targeted treatment approach that uses radioactive compounds linked to ligands to recognize and bind to cancer-specific markers. This therapy destroys cancer cells from within while minimizing damage to surrounding healthy tissue. For instance, in March 2025, Novartis AG, a Switzerland-based pharmaceutical company, launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which received approval from the US Food and Drug Administration (FDA). The therapy is intended for earlier use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received an androgen receptor pathway inhibitor (ARPI) and are suitable for delaying chemotherapy. Based on results from the Phase III PSMAfore trial, the expanded indication significantly increased the eligible patient population and demonstrated a 59% reduction in the risk of radiographic progression or death, while more than doubling median radiographic progression-free survival compared with a change in ARPI therapy. Pluvicto is the first targeted radioligand therapy approved for use prior to chemotherapy in this setting, providing a new treatment option that delays disease progression with a favorable safety profile.

In June 2024, AstraZeneca, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.4 billion. Through this acquisition, AstraZeneca aims to strengthen its oncology portfolio by adding next-generation radioconjugate therapies, including FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC), and to enhance its capabilities in radiopharmaceutical research and development, manufacturing, and supply. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on treatments for metastatic castration-resistant prostate cancer.

Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc.

North America was the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormone refractory prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hormone refractory prostate cancer market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing inputs, diagnostic reagents, and specialized medical equipment used in oncology care. North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces pricing pressures on oncology drug production and distribution. These tariffs are contributing to higher treatment costs and slower market access for novel therapies. However, they are also encouraging domestic drug manufacturing, localized clinical research, and greater investment in regional oncology production capabilities.

The hormone refractory prostate cancer market research report is one of a series of new reports that provides hormone refractory prostate cancer market statistics, including hormone refractory prostate cancer industry global market size, regional shares, competitors with a hormone refractory prostate cancer market share, detailed hormone refractory prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the hormone refractory prostate cancer industry. This hormone refractory prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hormone-refractory prostate cancer (HRPC), also known as castration-resistant prostate cancer (CRPC), is a form of prostate cancer that continues to progress despite achieving low testosterone levels through androgen deprivation therapy (ADT). This progression may be reflected by rising prostate-specific antigen (PSA) levels, radiographic evidence of new or enlarging tumors, or worsening clinical symptoms. HRPC represents an advanced and treatment-resistant stage of prostate cancer, often requiring additional systemic therapies beyond standard hormone suppression.

The primary treatment types for hormone-refractory prostate cancer include chemotherapy, hormonal therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy treats hormone-refractory prostate cancer by using potent drugs to target cancer that no longer responds to hormone therapy and has spread to other parts of the body. These treatments are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by end users including hospitals, ambulatory surgical centers, specialty clinics, and others.

The hormone-refractory prostate cancer (HRPC) market consists of revenues earned by entities by providing services such as oncology consultations, advanced imaging, molecular diagnostic testing, clinical trial participation, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hormone-refractory prostate cancer (HRPC) market also includes sales of next-generation androgen receptor inhibitors, radiopharmaceuticals, and bone health agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.